HAND1 Antibody

What is HAND1 and what cellular functions does it regulate?

HAND1 is a basic helix-loop-helix (bHLH) transcription factor that plays essential roles in embryonic development. It functions as a DNA-binding protein that recognizes the sequence 5'-NRTCTG-3' (non-canonical E-box) . HAND1 acts as a transcriptional regulator critical for proper development of multiple tissues and cell lineages.

The protein functions in several key developmental processes:

• Trophoblast giant cell differentiation essential for placenta development and function

• Cardiac morphogenesis and heart development

• Specification of multipotent cardiac progenitors

• Development of the sympathetic nervous system

• Formation of limb structures and jaw development

At the molecular level, HAND1 interacts with SOX15, with this interaction enhancing the differentiation of trophoblast giant cells . In adult tissues, HAND1 may be required for the continued expression of cardiac-specific genes .

What are the validated applications for HAND1 antibodies?

HAND1 antibodies have been validated for multiple research applications, as summarized in the following table:

When selecting antibodies for specific applications, researchers should consult validation data for their experimental system and optimize dilutions for each application as noted in product documentation .

Which tissues and cell types express HAND1?

HAND1 shows a specific expression pattern across multiple tissues and cell types during development:

Western blot analysis using HAND1 antibodies has detected expression in human heart tissue, human brain (cerebellum) tissue, and human placenta tissue , confirming these as key sources for HAND1 protein detection.

What is the expected molecular weight of HAND1 protein in antibody-based detection?

HAND1 protein has a calculated molecular weight of approximately 23-24 kDa:

When performing Western blot analysis, researchers should expect to detect a specific band for HAND1 at approximately 22 kDa, as demonstrated in lysates of human heart tissue, human brain (cerebellum) tissue, and human placenta tissue . It's important to note that post-translational modifications or experimental conditions may slightly affect the observed molecular weight.

What species reactivity is available for HAND1 antibodies?

HAND1 antibodies are available with varying degrees of species reactivity validation:

For species with predicted reactivity, additional validation steps are recommended to confirm antibody specificity in the experimental system being used.

How do HAND1 expression levels influence cell fate determination in cardiac development?

Recent research has revealed that HAND1 expression levels play a critical role in cell fate specification during cardiac development:

At the cellular level, HAND1 exhibits dosage-dependent effects on developmental trajectories:

• Low levels of HAND1 direct differentiation toward specific cardiac lineages

• Complete absence of HAND1 (HAND1-null) results in the loss of epicardial and fibroblast-like cell development

• HAND1-null cells show a single dominant trajectory to cardiomyocytes, in contrast to wild-type cells which exhibit multiple developmental pathways

• HAND1-null progenitors show increased expression of second heart field (SHF) markers (TBX1, JAG1, ISL1) and decreased expression of first heart field (FHF) marker TBX5

Mechanistically, HAND1 induces significant restructuring of chromatin, primarily in distal intergenic and intronic locations . HAND1 functions with multiple binding partners including GATA6, ZIC2/3, FOXO1, FOXF1, PBX/MEIS, and SMAD transcription factors .

Single-cell RNA-sequencing analysis confirms HAND1's role in the development of a multipotent progenitor population with distinct cell fate potential . The identification of HAND1 target genes through ChIP-seq revealed 335 activated and 350 repressed genes, with approximately half showing changes within 12 hours of HAND1 expression .

These findings underscore the importance of precise HAND1 levels in embryonic development, with implications for understanding congenital heart defects and cardiac development.

What methodological considerations apply when using HAND1 antibodies for lineage tracing experiments?

Lineage tracing experiments involving HAND1 require careful experimental design and antibody selection:

Methodology recommendations:

• Approach selection:

  • For real-time HAND1 expression: Use validated antibodies targeting native HAND1 protein

  • For lineage history: Consider genetic approaches using Cre-lox systems with reporter alleles, such as the Hand1EGFPCreΔNeo system described in the literature

  • Compare antibody-based detection with genetic lineage tracing for comprehensive analysis

• Tissue preparation and epitope accessibility:

  • HAND1 is primarily localized to the nucleus, requiring appropriate fixation and permeabilization

  • Optimize fixation conditions to preserve transcription factor epitopes

  • For SH-SY5Y cells, successful detection used immersion fixation followed by detection with 5 μg/mL antibody for 3 hours at room temperature

• Validation strategies:

  • Use HAND1-null tissues or cells as negative controls

  • Perform peptide competition assays with the immunizing peptide to confirm specificity

  • Compare antibody detection patterns with known HAND1 expression domains

• Multi-marker approaches:

  • Combine HAND1 antibody staining with lineage-specific markers

  • Use nuclear counterstains (DAPI) to confirm localization

  • Consider co-staining experiments with markers like Flk1 for vascular endothelium

The search results demonstrate that comparisons between antibody-detected HAND1 expression and genetic HAND1-lineage tracing have been instrumental in refining our understanding of HAND1's dynamic expression domains .

How can HAND1 antibodies be applied to study placental development and function?

HAND1 plays crucial roles in placental development, making HAND1 antibodies valuable tools for investigating this process:

Experimental approaches:

• Trophoblast differentiation studies:

  • HAND1 controls trophoblast differentiation essential for placental development

  • Use antibodies to monitor HAND1 expression during trophoblast giant cell formation

  • Investigate HAND1 interactions with regulatory partners like SOX15

• Placental structure analysis:

  • The HAND1 lineage contributes to multiple placental components including:

    • Trophoblast giant cells and labyrinthine cells

    • Endothelium and smooth muscle of the umbilical vein

    • Wharton's jelly surrounding the umbilical cord

    • Vitelline vessels and cells within the placental labyrinth

• Cell-type identification:

  • Use co-immunostaining approaches with HAND1 antibodies and cell-type markers

  • In placental labyrinth, complete overlap between HAND1-lineage (eGFP) and Flk1 was observed, indicating HAND1-lineage marks vascular endothelium

  • Complementary pattern with α-smooth muscle actin (αSMA) suggests smooth muscle derives from HAND1-independent lineages

• Methodological considerations:

  • For protein detection: Western blot analysis of placental tissue lysates

  • For spatial analysis: Immunohistochemistry or immunofluorescence of placental sections

  • For molecular interactions: Co-immunoprecipitation with HAND1 antibodies

These approaches enable researchers to investigate the complex roles of HAND1 in placental development, which is essential for embryonic survival and has implications for understanding pregnancy complications.

What technical challenges should researchers consider when using HAND1 antibodies for ChIP-seq experiments?

ChIP-seq studies with HAND1 antibodies present several technical considerations that require optimization:

Key challenges and recommendations:

• Binding site characteristics:

  • HAND1 binding occurs predominantly in distal intergenic and intronic locations

  • In mesoderm differentiation models, 25,517 and 34,211 HAND1 binding sites were identified in control and SB-treated conditions, respectively

  • Optimize chromatin shearing protocols to efficiently recover these regulatory regions

• Motif complexity and co-factors:

  • HAND1-bound regions are enriched for both the HAND1 motif (non-canonical E-box) and recognition motifs of other factors important in mesoderm development

  • Associated motifs include those for GATA6, EOMES, ZIC3, and TBX6

  • Consider sequential ChIP approaches to investigate co-binding with predicted partners

• Expression level effects:

  • HAND1 levels influence binding site selection and target gene regulation

  • For controlled studies, consider inducible expression systems like the doxycycline-inducible HAND1-BFP transgene approach described in the literature

  • Correlate ChIP-seq results with ATAC-seq to assess chromatin accessibility changes

• Target gene identification:

  • HAND1 regulates distinct sets of activated (335) and repressed (350) target genes

  • Activated targets are enriched for transcription factors, heart morphogenesis genes, and anterior-posterior pattern formation genes including HOX factors

  • Repressed targets include genes involved in neural development, WNT signaling, and endoderm development

• Validation approaches:

  • Confirm key binding sites with ChIP-qPCR using multiple HAND1 antibodies

  • Correlate binding with gene expression changes using RNA-seq

  • Use HAND1-null cells as negative controls

These technical considerations can help researchers design robust ChIP-seq experiments to investigate HAND1's gene regulatory networks in developmental processes.

How can researchers validate the specificity of HAND1 antibodies in their experimental systems?

Thorough validation of antibody specificity is essential for generating reliable data in HAND1 research:

Recommended validation strategies:

• Genetic controls:

  • Use HAND1-null cells or tissues as negative controls

  • Compare staining patterns across wild-type, heterozygous, and null samples

  • Consider using HAND1 overexpression systems as positive controls

• Peptide competition assays:

  • Pre-incubate antibody with the immunizing peptide to block specific binding

  • Run parallel experiments with blocked and unblocked antibody

  • Example: Immunofluorescence analysis of A459 cells with HAND1 antibody at 1/100 dilution showed specific signal elimination when treated with synthesized peptide

• Multiple antibody validation:

  • Test antibodies from different sources targeting different HAND1 epitopes

  • Compare results across antibodies (e.g., goat polyclonal vs. rabbit polyclonal )

  • Consistent results with multiple antibodies increases confidence in specificity

• Application-specific validation:

  • For Western blot: Confirm band size matches expected molecular weight (~22-24 kDa)

  • For immunofluorescence: Verify nuclear localization and compare to known expression patterns

  • For ChIP: Include IgG controls and validate enrichment at known HAND1 target regions

• Cross-technique validation:

  • Compare protein detection with mRNA expression data

  • Use HAND1 reporter systems (e.g., HAND1 LacZ) as reference for expected expression patterns

  • Correlate antibody staining with results from genetic lineage tracing approaches

These validation strategies help ensure that experimental results accurately reflect HAND1 biology rather than non-specific antibody interactions.

What are the technical considerations for detecting HAND1 in different cellular compartments?

Accurate detection of HAND1 in its relevant cellular locations requires specific technical approaches:

Methodological recommendations:

• Nuclear detection optimization:

  • As a transcription factor, HAND1 primarily localizes to the nucleus

  • In SH-SY5Y cells, "specific staining was localized to nuclei" using appropriate antibodies

  • Use nuclear counterstains (e.g., DAPI) to confirm proper localization

  • For Western blot applications, consider nuclear extraction protocols to enrich for HAND1

• Protocol optimization by application:

  • Immunofluorescence in fixed cells:

    • Successful detection in SH-SY5Y cells used 5 μg/mL antibody for 3 hours at room temperature

    • Use appropriate secondary antibodies (e.g., NorthernLights™ 557-conjugated Anti-Goat IgG)

  • Western blot:

    • PVDF membrane probed with 1 μg/mL HAND1 antibody

    • Use reducing conditions and appropriate buffer systems (e.g., Immunoblot Buffer Group 1)

  • Non-adherent cells:

    • Follow specialized protocols for non-adherent cell types

    • Consider fixation in suspension before processing

• Fixation and permeabilization:

  • Optimize fixation to preserve nuclear transcription factor epitopes

  • For immunofluorescence, immersion fixation has been successful for HAND1 detection

  • Ensure adequate permeabilization for nuclear antigen access

  • Test multiple antibody dilutions to optimize signal-to-noise ratio

• Storage and handling:

  • Store antibodies according to manufacturer recommendations

  • Typical storage: -20°C with 50% glycerol and 0.02% sodium azide

  • Aliquot to avoid freeze-thaw cycles for sensitive antibodies

  • Validate stability after storage according to expected timeframes (e.g., "stable for one year after shipment")

These technical considerations help ensure accurate detection of HAND1 in its relevant cellular compartments, which is crucial for understanding its biological functions in development and disease models.